CinCor Pharma (NASDAQ: CINC) soared by more than 135% in pre-market trading on Monday after AstraZeneca (AZN) announced the acquisition of the clinical-stage biopharmaceutical company for $1.8 billion.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
According to the terms of the agreement, AZN will acquire all outstanding shares of CinCor at a price of $26 per share in cash in addition to a “non-tradable contingent value right of $10 per share in cash payable upon a specified regulatory submission of a baxdrostat product.”
This price represents a 121% premium over CinCor’s closing market price on 06 January 2023. AZN will also acquire the cash and marketable securities on CinCor’s balance sheet of around $522 million as of 30 September 2022.
Through this acquisition, AZN is looking at bolstering its cardiorenal pipeline by the addition of CInCor’s candidate drug, baxdrostat (CIN-107), an aldosterone synthase inhibitor (ASI) used to lower treatment-resistant hypertension.